Company: GANX
Filing Date: 2025-07-15
Form Type: 424B5
Source: 0001104659-25-068103
Chunk: 21

Company: Gain Therapeutics, Inc.
Filing Date: 2025-07-15
Form: 424B5
Chunk 21
---
ing the underwriting discount and commissions and estimated offering expenses payable by us, and excluding the proceeds, if any, from the exercise of the Pre-Funded Warrants or Common Warrants issued in this offering.

If all of the Common Warrants sold in this offering were to be exercised in cash at the exercise price of $ per share, we would receive additional proceeds of approximately $ million. However, the Common Warrants contain a cashless exercise provision that permit exercise on a cashless basis at any time where there is no effective registration statement under the Securities Act covering the issuance of the underlying shares. We cannot predict when or if the Common Warrants will be exercised or whether they will be exercised for cash. It is possible that the Common Warrants may be exercised solely on a cashless basis or not at all.

We intend to use the net proceeds of this offering to continue clinical and nonclinical development of our lead product candidate GT-02287 for the treatment of neurodegenerative diseases including GBA1 Parkinson’s disease and for general corporate purposes.

The timing and amounts of our actual expenditures will depend on several factors, including the progress of our research and development programs, the results of other pre-clinical and clinical studies and the timing and costs of regulatory approvals. Pending the uses described above, we will invest the net proceeds in short-term and long-term, investment grade, interest-bearing securities.

<div align='center'>S-14</div>

TABLE OF CONTENTS

### DESCRIPTION OF SECURITIES WE ARE OFFERING

#### Common Stock
For a description of our common stock, see “Description of Capital Stock” beginning on page 11of the accompanying prospectus.

The transfer agent and registrar for our common stock is Pacific Stock Transfer Company, 6725 Via Austi Pkwy, Suite 300, Las Vegas, NV 89119.

#### Pre-Funded Warrants
The material terms and provisions of the Pre-Funded Warrants being issued in this offering are summarized below. The following description is subject to, and qualified in its entirety by, the form of Pre-Funded Warrant which will be filed as an exhibit to a Current Report on Form 8-K to be filed by us with the SEC in connection with this offering. You should review the form of Pre-Funded Warrant for a complete description of the terms and conditions applicable to the Pre-Funded Warrants.

Exercise Price. The initial exercise price is $0.0001 per share of common stock. The exercise price is subject to appropriate adjustment